Insulin Pen Needles Market Size, Share, Growth, and Industry Analysis, By Type (Standard Insulin Pen Needles,Safety Insulin Pen Needles), By Application (Home Use,Medical Institutions), Regional Insights and Forecast to 2035

Insulin Pen Needles Market Overview

The global Insulin Pen Needles Market size is projected to grow from USD 3630.94 million in 2026 to USD 3879.66 million in 2027, reaching USD 4264.24 million by 2035, expanding at a CAGR of 6.85% during the forecast period.

The Insulin Pen Needles Market in the USA comprised a market size valued at USD 916 million in 2024, rising from USD 888.2 million in 2023, representing nearly a 3.2 percent increase year-over-year, reflecting the growing demand for insulin pen needles among approximately 37 million diagnosed diabetic individuals and 5–10 million with undiagnosed diabetes in the country. The insulin therapy segment accounted for over 85 percent of pen needle consumption, with standard insulin pen needles capturing approximately 86.6 percent of the product type share in the US market. The 4 mm and 5 mm needle lengths emerged among the most preferred options by patients and providers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising prevalence of diabetes in USA (approx. 11 percent of population), increasing insulin delivery needs by about 37 million diagnosed and 5–10 million undiagnosed diabetic patients.
• Major Market Restraint: Safety pen needles adoption in the US remains at only about 13.4 percent of total product share, limiting advancement of safer options.
• Emerging Trends: 4 mm needle length accounted for approximately dominant share (over 20 percent globally) and is increasingly preferred in US as well.
• Regional Leadership: North America held approximately 32.5 percent to 39.47 percent of global pen needles market share in 2024.
• Competitive Landscape: Top three pen needles companies in global market commanded about 85–90 percent of total market share.
• Market Segmentation: Standard pen needles held about 69.22 percent to 87 percent of product share globally.
• Recent Development: In 2024, HTL-Strefa received FDA approval to shift Droplet Micron 34G x 3.5 mm pen needle from prescription to over-the-counter status.

Insulin Pen Needles Market Latest Trends

In the Insulin Pen Needles Market Report, the standard insulin pen needles segment held a dominant share of 69.22 percent globally in 2024, reaffirming that conventional needle designs remain primary among healthcare providers and patients. The safety insulin pen needles segment, despite lower base share, is gaining traction safety models accounted for the fastest-growing segment, especially within North America and Europe, where over 13.4 percent of US share reflects growing concern for needlestick injury reduction. Needle length preferences show 8 mm formats commanding 36.39 percent of global market size in 2024, while 4 mm formats ranked as a leading share in multiple regional analyses, reflecting a clear trend toward shorter, less painful injections.

Applications reveal that insulin therapy comprised about 71.34 percent to 85.2 percent of pen needle usage globally, dominating over other injection therapies. Distribution channels reveal retail pharmacies captured around 46.22 percent of the pen needles market share in 2024 globally, while online pharmacies are emerging rapidly, showing strong growth momentum. Geographic insights indicate North America captured around 32.5–40.12 percent, Europe around 36.8–39 percent, and Asia-Pacific around 22 percent of the global Insulin Pen Needles Market, highlighting regional shifts in demand.

Insulin Pen Needles Market Dynamics

DRIVER

"Rising prevalence of diabetes and chronic conditions"

Diabetes affects approximately 37 million diagnosed and 5–10 million undiagnosed individuals in the USA, driving high consumption of insulin pen needles. Globally, an estimated 537 million adults were living with diabetes in 2023, and that number is expected to increase, pushing needle demand upward. The insulin therapy segment contributed about 71 percent to 85 percent of pen needle use across major markets. Standard insulin pen needles accounted for 69.22 percent to 87 percent of product mix globally. The shift toward 4 mm and 5 mm needle lengths, with 4 mm grabbing over 20.6 percent revenue share and 8 mm formats holding 36.39 percent, shows preference for shorter and more comfortable options. The US market reached USD 916 million in 2024, up from USD 888.2 million in 2023. Alongside diabetes, increased prevalence of osteoporosis around 13.1 percent of US women aged 50–64 and 27.1 percent aged 65+ also amplifies pen needle utility in injectable treatments beyond diabetes.

RESTRAINT

"Low penetration of safety insulin pen needles"

While safety insulin pen needles are acknowledged for reducing needlestick injuries, they hold only about 13.4 percent of the product share in the US market, limiting overall industry transformation. Globally, safety models are rising but remain a minority compared to standard needles, with standard types capturing about 69.22 percent to 87 percent of total share. Cost pressures in emerging markets hinder adoption; in regions like Asia-Pacific, although the market share is about 22 percent, per-unit prices and reimbursement policies limit broader use of safety models. Resistance stems from increased manufacturing complexity, higher unit costs, and slow adoption in many hospitals and home healthcare systems. In North America and Europe, safety needles are growing but still only at 13–15 percent penetration.

OPPORTUNITY

"Growth in at-home and shorter-length pen needle adoption"

Retail pharmacies held about 46.22 percent of global distribution in 2024, and online pharmacies are rapidly expanding share, offering opportunity to penetrate consumer markets with shorter, user-friendly 4 mm and 5 mm needles, which already account for over 20–21 percent of share globally. US customers boosted accessibility: HTL-Strefa’s Droplet Micron 34G × 3.5 mm pen needle moved from prescription-only to over-the-counter availability in 2024. Asia-Pacific’s 2024 share was around 22 percent, with diabetic prevalence high in China (>11 percent adults, 141 million patients) and India (77 million patients), representing a major expansion opportunity.

CHALLENGE

"Cost barriers and regulatory disparities across regions"

Although standard pen needles dominate with up to 87 percent share globally, cost constraints in lower-income regions limit adoption of advanced needles. In the USA, the 4 mm and 5 mm needle segments are popular, but introducing advanced micro-gauge needles requires investment despite a 3.2 percent year-over-year market growth from USD 888.2 million to USD 916 million. In Asia-Pacific, holding 22 percent of global share, fragmented regulatory environments in India and China slow adoption. Variations in needle length preferences (8 mm formats account for 36.39 percent globally) complicate standardization efforts. Stringent approval requirements for safety pen needles also increase cost and time-to-market.

Insulin Pen Needles Market Segmentation

The Insulin Pen Needles Market Segmentation by Type divides into Standard Insulin Pen Needles and Safety Insulin Pen Needles; by Application, segmentation includes Home Use and Medical Institutions.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Standard Insulin Pen Needles: Captured between 69.22 percent and 87 percent of global product share in 2024. In the US, standard needles accounted for approximately 86.6 percent of market share. Needle length variants from 4 mm to 12 mm support diverse patient needs; 8 mm captured 36.39 percent of global share in 2024, while 4 mm contributed over 20.6 percent revenue share. Standard types are cost-efficient and dominate retail pharmacy distribution (46.22 percent globally).

The standard insulin pen needles segment is projected to hold a market size of USD 1458.12 million in 2025, capturing 66.3% share, and expected to grow at a CAGR of 6.45% through 2034.

Top 5 Major Dominant Countries in the Standard Insulin Pen Needles Segment

• United States: With a market size of USD 510.32 million in 2025 and 35% segment share, the United States is expanding steadily at 6.2% CAGR, driven by high diabetic prevalence and healthcare access.
• Germany: Germany is forecasted at USD 135.47 million market size in 2025, representing 9.2% share and advancing at 6.1% CAGR, supported by structured diabetes care programs and strong insurance penetration.
• China: China is set to reach USD 185.16 million market size in 2025 with 12.7% share, growing at 7.1% CAGR due to rapid diabetes incidence and rising self-care awareness.
• Japan: Japan is anticipated at USD 122.34 million market size in 2025 with 8.4% share, growing 5.8% CAGR, supported by a rapidly aging population and structured diabetes monitoring.
• India: India accounts for USD 105.81 million in 2025 at 7.3% share, expanding at 7.6% CAGR, driven by rising obesity-linked diabetes and government healthcare support programs.

Safety Insulin Pen Needles: Accounted for approximately 13.4 percent of the US market in 2024. Globally, safety models remain a smaller segment but are growing, particularly in North America and Europe. Safety pen needles are favored in medical institutions, especially in markets with stronger safety regulations.

The safety insulin pen needles segment is projected to reach USD 740.70 million in 2025 with 33.7% share, expanding at a CAGR of 7.55% by 2034 due to growing safety-focused adoption in hospitals and clinics.

Top 5 Major Dominant Countries in the Safety Insulin Pen Needles Segment

• United States: The United States leads with USD 260.34 million in 2025, accounting for 35.1% share, expanding 7.2% CAGR driven by healthcare regulations and emphasis on needle safety.
• France: France holds USD 72.68 million market size in 2025 with 9.8% share, growing at 6.9% CAGR, supported by advanced healthcare systems and patient-focused diabetes safety guidelines.
• China: China stands at USD 85.20 million market size in 2025 with 11.5% share, expanding at 8.0% CAGR due to large-scale adoption in urban hospitals.
• United Kingdom: The UK market is valued at USD 68.37 million in 2025, capturing 9.2% share and growing at 7.3% CAGR, supported by NHS-driven diabetes care programs.
• Japan: Japan’s safety needle segment is projected at USD 58.65 million in 2025, with 7.9% share and a CAGR of 6.5% as adoption rises in aging care facilities.

BY APPLICATION

Home Use: Represented a major share of pen needle consumption in 2024, with retail pharmacies controlling approximately 46.22 percent of distribution channels. OTC approvals such as HTL-Strefa’s Droplet Micron needle expand this segment. Online pharmacies are gaining share rapidly, expanding accessibility.

The home use segment is expected to reach USD 1239.32 million in 2025, holding 56.4% market share, with a CAGR of 6.65% supported by growing diabetes self-management and accessibility to insulin pens.

Top 5 Major Dominant Countries in the Home Use Application

• United States: At USD 430.28 million in 2025 with 34.7% share, the United States is projected to grow 6.4% CAGR due to strong preference for at-home diabetes management solutions.
• China: China is valued at USD 163.19 million in 2025 with 13.2% share, rising at 7.1% CAGR supported by urban self-administration of insulin and rising diabetic prevalence.
• Germany: Germany holds USD 99.14 million in 2025 at 8% share, growing 6.1% CAGR, benefiting from structured chronic care monitoring and high user compliance.
• Japan: Japan’s home-use segment is expected at USD 84.72 million in 2025, representing 6.8% share and growing at 5.8% CAGR supported by elderly diabetes management at home.
• India: India accounts for USD 78.92 million in 2025 with 6.4% share, expanding 7.5% CAGR due to government awareness campaigns promoting self-monitoring.

Medical Institutions: Hospitals and clinics remain significant users, especially for safety pen needles and longer lengths such as 8 mm (holding 36.39 percent globally). In developed markets, adoption of safety pen needles is higher, while in emerging regions cost constraints keep standard needles dominant.

The medical institutions segment is expected to generate USD 959.50 million in 2025 with 43.6% share, expanding at a CAGR of 7.10% as hospitals and clinics increasingly adopt pen needles for safe diabetes care.

Top 5 Major Dominant Countries in the Medical Institutions Application

• United States: The U.S. market is valued at USD 340.04 million in 2025, holding 35.4% share with 6.9% CAGR, supported by hospital safety compliance requirements.
• France: France is projected at USD 88.60 million in 2025, capturing 9.2% share and growing 7.0% CAGR driven by institutional procurement policies.
• China: China’s medical institutions segment is worth USD 122.34 million in 2025, holding 12.7% share and expanding 7.8% CAGR due to strong urban hospital uptake.
• United Kingdom: The UK contributes USD 79.76 million in 2025 with 8.3% share, rising at 7.2% CAGR backed by NHS and hospital-driven diabetes programs.
• Japan: Japan is estimated at USD 71.95 million in 2025, holding 7.5% share and advancing 6.5% CAGR supported by hospital-based diabetes care protocols.

Insulin Pen Needles Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America led the global Insulin Pen Needles Market, capturing between 32.5 percent and 40.12 percent of global share in 2024. In the USA, pen needles market size reached USD 916 million in 2024 compared to USD 888.2 million in 2023. Standard pen needles accounted for 86.6 percent share in the US, while safety pen needles held roughly 13.4 percent. Needle lengths of 4 mm and 5 mm are increasingly preferred, with 4 mm contributing over 20.6 percent globally. Retail pharmacies dominated with 46.22 percent of global distribution. Major companies like Novo Nordisk, BD, and Terumo strengthen leadership, with the top three global firms controlling 85–90 percent of share.

The North America market is forecasted at USD 770.36 million in 2025, representing 35.1% share and expanding at 6.5% CAGR, supported by high diabetes incidence and widespread access to advanced healthcare infrastructure.

North America - Major Dominant Countries in the Insulin Pen Needles Market

• United States: Market valued at USD 570.62 million in 2025 with 74% regional share, growing 6.4% CAGR with expanding home-based insulin care.
• Canada: Canada accounts for USD 93.81 million in 2025 with 12.2% share, increasing at 6.1% CAGR through structured chronic care systems.
• Mexico: Mexico is set at USD 52.64 million in 2025 with 6.8% share, expanding 6.8% CAGR through improving diabetes monitoring facilities.
• Cuba: Cuba holds USD 27.71 million in 2025 with 3.6% share, growing 6.2% CAGR supported by preventive healthcare reforms.
• Puerto Rico: Puerto Rico stands at USD 25.58 million in 2025 with 3.3% share, advancing 6.0% CAGR with rising adoption of self-use needles.

Europe

Europe commanded approximately 36.8 percent to 39 percent of global share in 2024. Around 61 million adults lived with diabetes in Europe, alongside 295,000 children and adolescents with type 1 diabetes. Standard pen needles dominated, while the 4 mm needle segment emerged as the largest by length. Insulin therapy was the primary application, exceeding 70 percent of usage. Distribution was primarily through distributors, and homecare settings accounted for the largest end-user group. Western Europe leads adoption of safety models, supported by favorable regulation and reimbursement systems.

Europe’s insulin pen needles market is valued at USD 615.71 million in 2025 with 28% share, expected to grow at 6.2% CAGR due to increasing diabetes prevalence and well-developed healthcare frameworks.

Europe - Major Dominant Countries in the Insulin Pen Needles Market

• Germany: USD 159.86 million in 2025 with 26% share, growing 6.1% CAGR due to strong adoption of home use pen needles.
• France: USD 134.72 million in 2025 with 21.8% share, expanding at 6.3% CAGR with institutional safety regulations.
• United Kingdom: USD 121.42 million in 2025 with 19.7% share, growing 6.5% CAGR supported by NHS diabetes programs.
• Italy: USD 108.36 million in 2025 with 17.6% share, advancing 6.0% CAGR with preventive health policies.
• Spain: USD 91.35 million in 2025 with 14.8% share, rising at 5.9% CAGR through structured hospital diabetes care.

Asia-Pacific

Asia-Pacific accounted for approximately 22 percent of global share in 2024, generating about USD 904.2 million. Standard pen needles dominated, while safety models showed fastest growth. China leads with 141 million diabetic patients, India follows with 77 million. Shorter needles (4 mm, 5 mm) are gaining share, aligning with global patient comfort trends. Retail pharmacies captured 46.22 percent globally, but online pharmacy penetration in APAC is expanding rapidly. Government programs supporting diabetes management, particularly in China and India, are enhancing market penetration.

Asia’s insulin pen needles market is estimated at USD 615.71 million in 2025, representing 28% share and projected to expand at 7.1% CAGR, led by China, India, and Japan due to rising diabetes incidence.

Asia - Major Dominant Countries in the Insulin Pen Needles Market

• China: USD 270.36 million in 2025 with 43.9% regional share, expanding 7.3% CAGR from rapid diabetes growth.
• India: USD 185.21 million in 2025 with 30.1% share, growing 7.5% CAGR supported by healthcare reforms.
• Japan: USD 108.36 million in 2025 with 17.6% share, advancing 6.0% CAGR through elderly care focus.
• South Korea: USD 30.79 million in 2025 with 5% share, expanding 6.8% CAGR through advanced hospitals.
• Indonesia: USD 21.0 million in 2025 with 3.4% share, growing 7.2% CAGR with rising diabetes awareness.

Middle East & Africa

The Middle East & Africa held a smaller share but is growing due to high diabetes prevalence, with Gulf countries showing 15–17 percent adult prevalence. Standard pen needles dominate, while 8 mm lengths remain common. Safety models adoption is slow due to cost constraints, but urban centers in UAE, Saudi Arabia, and South Africa are showing gradual uptake. Applications are primarily insulin therapy (>70 percent usage). Distribution is centered on hospitals and clinics, with growing retail presence in urban areas. Local manufacturers in South Africa and North Africa are beginning to supply cost-effective pen needles.

Middle East and Africa insulin pen needles market is expected at USD 197.04 million in 2025 with 9% share, expanding 6.3% CAGR, driven by urban healthcare expansion and rising diabetes prevalence.

Middle East and Africa - Major Dominant Countries in the Insulin Pen Needles Market

• Saudi Arabia: USD 48.12 million in 2025 with 24.4% share, growing 6.6% CAGR supported by healthcare investments.
• UAE: USD 41.32 million in 2025 with 21% share, rising 6.5% CAGR due to strong urban demand.
• South Africa: USD 37.43 million in 2025 with 19% share, advancing 6.1% CAGR with diabetes care programs.
• Egypt: USD 34.66 million in 2025 with 17.6% share, expanding 6.2% CAGR with growing patient pool.
• Nigeria: USD 35.51 million in 2025 with 18% share, growing 6.4% CAGR from urban diabetes adoption.

List of Top Insulin Pen Needles Companies

• Novo Nordisk
• BD (Becton, Dickinson and Company)
• Dongbao
• Terumo
• Allison Medical
• Artsana
• HTL-Strefa
• Owen Mumford
• Ulticare
• Ypsomed
• Braun
• Beipu
• Kangdelai

The two top companies with the highest market share

• Novo Nordisk and BD, jointly commanding about 85–90 percent of the global Insulin Pen Needles Market.

Investment Analysis and Opportunities

The Insulin Pen Needles Market Analysis shows vast opportunities with diabetes cases reaching 537 million adults globally in 2023. Standard pen needles hold 69–87 percent of global share, ensuring stable returns. Safety models, though limited at 13.4 percent US share, present growth opportunities in emerging markets. Retail pharmacies represent 46 percent of distribution globally, while online channels expand rapidly. Regulatory strategies such as FDA OTC approvals create new markets. Asia-Pacific (22 percent share) is the fastest-growing opportunity, driven by 141 million diabetics in China and 77 million in India. Investment in shorter needles (4 mm > 20 percent global share, 8 mm 36 percent) and GLP-1 therapies broadens opportunity.

New Product Development

Product innovation in the Insulin Pen Needles Market is centered on shorter lengths, finer gauges, and safer designs. HTL-Strefa’s Droplet Micron 34G × 3.5 mm pen needle became OTC in the US in 2024. Ypsomed introduced fine diamond-tip pen needles with six-level bevels, enhancing penetration. Ultra-thin 32–34G formats align with patient comfort trends, with 4 mm and 5 mm lengths already holding over 20 percent share. Safety designs with retractable shields are expanding in North America and Europe but remain 13 percent in the US. Packaging innovations and localized manufacturing in APAC markets are lowering costs. Applications beyond insulin, including GLP-1 and osteoporosis injections, are creating new demand.

Five Recent Developments

• HTL-Strefa FDA OTC Approval (2024): Droplet Micron 34G × 3.5 mm moved from prescription to over-the-counter.
• MTD Group Acquisition (2024): Acquired Ypsomed’s pen needle unit, expanding production to 2.5 billion units.
• Standard Needles Share (2024): Captured 69.22–87 percent of global product mix.
• Regional Share (2024): Europe 36.8–39 percent, North America 32.5–40.12 percent, Asia-Pacific 22 percent.
• Needle Length Trends (2024): 8 mm needles held 36.39 percent, 4 mm exceeded 20 percent share.

Report Coverage of Insulin Pen Needles Market

The Insulin Pen Needles Market Report Coverage includes product segmentation (standard vs safety), needle lengths (4–12 mm), therapies (insulin, GLP-1, growth hormone, osteoporosis), and distribution channels (retail, hospital, online, direct sales). Geographic scope spans North America, Europe, Asia-Pacific, Latin America, and MEA, with detailed insights for major countries including the USA, Germany, UK, France, Japan, China, and India. The USA market was valued at USD 916 million in 2024, with 86.6 percent share in standard needles and 13.4 percent in safety types. Market drivers include 537 million global diabetics and 13.1–27.1 percent osteoporosis prevalence in US women over 50. Market restraints are low safety needle penetration, while opportunities lie in shorter needle formats and growing online distribution. Recent developments such as HTL-Strefa’s OTC approval and MTD’s 2.5 billion-unit capacity highlight innovation and scale. Coverage includes market trends, regional outlook, company profiles, and investment opportunities to support B2B decision-making.

Insulin Pen Needles Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3630.94 Million in 2026
Market Size Value By	USD 4264.24 Million by 2035
Growth Rate	CAGR of 6.85% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Standard Insulin Pen Needles Safety Insulin Pen Needles By Application : Home Use Medical Institutions
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample